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Abstract
Background: Granulocyte-macrophage colony stimulating factor (GM-CSF) is a hematopoietic
growth factor involved in the generation of granulocytes, macrophages, and dendritic cells from
hematopoietic progenitor cells. We have recently demonstrated that GM-CSF has anti-apoptotic
functions on neurons, and is neuroprotective in animal stroke models.
Results: The GM-CSF receptor α is expressed on adult neural stem cells in the rodent brain, and
in culture. Addition of GM-CSF to NSCs in vitro increased neuronal differentiation in a dose-
dependent manner as determined by quantitative PCR, reporter gene assays, and FACS analysis.
Conclusion: Similar to the hematopoietic factor Granulocyte-colony stimulating factor (G-CSF),
GM-CSF stimulates neuronal differentiation of adult NSCs. These data highlight the astonishingly
similar functions of major hematopoietic factors in the brain, and raise the clinical attractiveness of
GM-CSF as a novel drug for neurological disorders.
Background
Granulocyte-macrophage colony stimulating factor (GM-
CSF) is a hematopoietic growth factor involved in the gen-
eration of granulocytes, macrophages, and dendritic cells
from hematopoietic progenitor cells [1]. The GM-CSF
receptor is a heterodimer of the GM-CSF receptor α subu-
nit and the β subunit which is not directly involved in
binding GM-CSF. GM-CSF is used clinically in the field of
oncology and hematology [2]. Recently we have identified
GM-CSF as a neuronal growth factor in the brain which
counteracts apoptosis, and reduces infarct size in stroke
models in vivo [3]. GM-CSF has also been identified as a
factor involved in arteriogenesis after brain ischemia
[4,5]. GM-CSF is therefore the third hematopoietic factor
after EPO and G-CSF that has functions in the brain.
GM-CSF has very similar characteristics to G-CSF in the
brain in terms of patterns of expression, anti-apoptotic
functions, and neuroprotective effects [3]. G-CSF has a
prominent effect on the neuronal differentiation of adult
neural stem cells [6]. We therefore determined whether
GM-CSF might have a similar role also on the differentia-
tion of stem cells.
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Results
The GM-CSF receptor alpha is expressed on adult neural 
stem cells
The GM-CSF receptor is expressed in a broad variety of
brain regions, with a preferentially neuronal expression
pattern [3]. We also detected expression in regions where
neural stem cells persist in the adult brain, such as the
dentate gyrus. GM-CSFR α was expressed by cells in the
subgranular zone, and in cells of the granular layer that
are reminiscent of migrating stem cells (Figure 1A, B). We
also detected expression of the receptor on adult neural
stem cells from the hippocampus, that also stained posi-
tive for the stem cell marker nestin (Figure 1C–E). Stem
cells in culture also expressed the GM-CSF receptor as
judged by RT-PCR (Figure 1F).
GM-CSF promotes neuronal differentiation of adult neural 
stem cells
We therefore asked whether GM-CSF influenced the dif-
ferentiation of adult neural stem cells. To determine if
GM-CSF potentially influenced the generation of mature
neural cell types we assayed the expression of the neuro-
nal marker genes β-III-tubulin and neuron-specific eno-
lase (NSE), the oligodendrocytic marker proteolipid
protein (PLP), and the astrocytic marker glial fibrillary
acidic protein (GFAP) by quantitative PCR (qPCR) in
adult neural stem cells (NSCs). 3 days after GM-CSF treat-
ment (10 ng/ml) of adult neural stem cells we detected a
significant induction of β III-tubulin, and a non-signifi-
cant elevation of NSE, whereas regulation of PLP or GFAP
was not detectable (Figure 2A).
To determine whether this induction of mature neuronal
marker expression was concentration-dependent, we
assayed GM-CSF-induced differentiation by a luciferase
reporter assay [6]. Adult neural stem cells were transfected
with the pGL3-p-βIII-tubulin reporter vector and stimu-
lated with increasing concentrations of GM-CSF (0.5 – 10
ng/ml). We detected a concentration-dependent activa-
tion of the β III-tubulin promoter after 48 h of GM-CSF
exposure (Figure 2B). As positive control, NSCs were
treated with the standard differentiation protocol involv-
ing withdrawal of EGF and bFGF, and addition of FCS. 10
ng/ml GM-CSF had the same induction potential com-
pared to this standard protocol.
While the above assays measure marker induction on the
cell population level, we used fluorescence-activated cell
counting to determine differentiation on the cellular level.
The percentage of MAP-2-positive cells doubled under
GM-CSF treatment (Figure 2C). In summary, GM-CSF
promoted neuronal differentiation of neural stem cells in
vitro.
Discussion
Recently we uncovered that the hematopoietic factor GM-
CSF is also a neuronal growth factor with strong anti-
apoptotic actions on neurons [3]. This characteristic is
shared with two other important hematopoietic factors,
EPO and G-CSF. On top of these anti-apoptotic proper-
ties, both hematopoietic factors also display neurogenic
activities. EPO enhances neuronal differentiation of neu-
ral stem cells in vitro [7,8], EPO-receptor deficient mice
display reduced embryonic neurogenesis [7,9], mice with
a brain-specific knock-down of the EPO receptor show a
decrease in stroke-induced neurogenesis and migration
[9], and exogenously added EPO enhances neurogenesis
and behavioural outcome after injury models in vivo
[10,11]. Likewise, the G-CSF receptor is expressed on neu-
ral stem cells in the brain and in vitro [6], G-CSF stimu-
lates neuronal differentiation of neural stem cells in vitro
[6], and treatment of animal injury models with G-CSF
enhances neurogenesis and functional recovery [6,12-14].
Positive effects of G-CSF on neurogenesis in an animal
model for Alzheimer's disease have also been described
[15]. The multimodal efficacy of these factors, combined
with their established safety in other indications, has led
to a number of clinical trials in stroke patients [16-19].
GM-CSF is a likewise attractive candidate for clinical
development, because it is clinically in use for a number
of years in hematological indications, is anti-apoptotic
and neuroprotective in vivo, passes the intact blood-brain
barrier [3], and also has a neurogenic potential, likely ben-
eficial for long-term stroke recovery. Further studies need
to address issues of functional recovery and neurogenesis
in rodent stroke models.
Presence of the GM-CSF receptor has also been identified
on neuroepithelial cells from embryonic mouse brains
[20]. Addition of GM-CSF at concentrations of 0.05 to 5
μg/ml for 48 h inhibited staurosporine-induced apopto-
sis, and increased the number and diameter of stem cell
colonies. With addition of 0.5 μg/ml GM-CSF for 48 h the
authors report a diminished number of MAP-2 and GFAP-
positive cells, indicating a potential negative impact of
GM-CSF on (neuronal) differentiation. In general these
data from the embryo support our findings on adult neu-
ral stem cells, with regard to presence of the receptor on
neural stem cells, and anti-apoptotic actions of GM-CSF
[3]. However, there is an apparent discrepancy in the role
of GM-CSF in differentiation. While it is possible that
there is a principle switch in the function of GM-CSF from
a more proliferation-enhancing growth factor at the
embryonic stage to a differentiation-enhancing factor in
adult life, there are a number of important differences
between both studies that make final conclusions diffi-
cult. The most prominent relate to the concentrations of
GM-CSF employed by Kim et al., that appear unphysio-
logically high for a growth factor (500 ng/ml by Kim et al.BMC Neuroscience 2007, 8:88 http://www.biomedcentral.com/1471-2202/8/88
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GM-CSFR alpha is present on adult neural stem cells Figure 1
GM-CSFR alpha is present on adult neural stem cells. A, B, GM-CSF receptor α is expressed on cells in the subgranu-
lar zone of the dentate gyrus, and in cells with extended processes in the granular cell layer that are reminiscent of migrating 
neural stem cells (A, 10× original magnification; B, 40× original magnification). C-E Hippocampal adult neural stem cells in cul-
ture also express the GM-CSF receptor α. The expression of the GM-CSF α receptor (C) colocalizes with the expression of 
the stem cell marker nestin (D) on an adult neural stem cell. E, merged image (all size bars 50 μm). F, RT-PCR demonstrates 
presence of the GM-CSF receptor on naive NSCs from the hippocampus (HC) and subventricular zone (SVZ) in vitro.
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GM-CSF induces neuronal differentiation of adult neural stem cells Figure 2
GM-CSF induces neuronal differentiation of adult neural stem cells. A, Expression of neural markers in stem cells. 3d 
after GM-CSF treatment of adult neural stem cells, the upregulation of the neuronal markers β III-tubulin and NSE (neuron 
specific enolase) was measured by qPCR. Note that there is significant induction of β III-tubulin (*, p<0.05, two-tailed t-test) 
whereas regulation of PLP or GFAP was not detectable. B, GM-CSF drives concentration-dependent neuronal differentiation 
of NSCs. For the luciferase reporter assay, adult neural stem cells were transfected with the pGL3-p-βIII-tubulin reporter vec-
tor and stimulated with increasing concentrations of GM-CSF. 48 h after stimulation, a concentration-dependent activation of 
the βIII-tubulin promoter was detected. As positive control, NSCs were treated with the standard differentiation protocol 
involving withdrawal of EGF and bFGF, and addition of FCS (*, p<0.05 by ANOVA and Newman-Keuls post-hoc test). C, Anal-
ysis of neuronal differentiation on the cellular level. FACS analysis demonstrating stem cells positive for the neuronal marker 
MAP-2 after treatment with GM-CSF. The percentage of MAP-2-positive cells is doubled under GM-CSF treatment (*, p<0.05, 
two-tailed t-test). All data are shown as mean ± SEM.
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vs. 10 ng/ml used in the above experiments). At least for
EPO, similar functions on embryonic and adult stem cells
have been described [8].
Conclusion
Here we have shown that the GM-CSF receptor is
expressed on adult neural stem cells, and that GM-CSF
induces dose-dependent neuronal differentiation of these
cells. This property places GM-CSF together with other
hematopoietic factors that have recently been shown to
function also as growth factors in the brain. On hemat-
opoietic stem cells, GM-CSF induces the generation and
maturation of neutrophilic granulocytes and monocytes/
macrophages. A similar role of GM-CSF in hematopoietic
and neural differentiation underlines the similarities that
exist between the two stem cell populations [21,22]. It
appears that the hematopoietic factors EPO, G-CSF, and
GM-CSF have all evolved to serve basic cellular functions
such as anti-apoptosis and differentiation in two different
body compartments.
Methods
Cultivation of adult neural stem cells (NSCs)
Neural stem cells were obtained from the hippocampus or
subventricular zone of 4–6 week old male Wistar rats as
described [23]. Briefly, animals were sacrificed, brains dis-
sected, washed in ice-cold Dulbecco's Phosphate Buffered
Saline (DPBS) containing 4.5 g/L glucose (DPBS/Glc).
The hippocampus and subventricular zone were dissected
from 6 animals, washed in 10 ml DPBS/Glc, and centri-
fuged for 5 min at 1600 g at 4°C. Tissue was minced by
scissors. Tissue pieces were washed again, centrifuged for
5 min at 800 g, and the pellet resuspended in 0.01 % (w/
v) papain, 0.1 % (w/v) Dispase II (neutral protease), 0.01
% (w/v) DNase I, and 12.4 mM manganese sulfate in
Hank's Balanced Salt Solution (HBSS). Tissue was incu-
bated for 40 min at room temperature.
Subsequently, the suspension was centrifuged at 4°C for
5 min at 800 g, and the pellet washed three times in 10 ml
DMEM-Ham's F-12 Medium containing 2 mM L-
Glutamin, 100 units/ml penicillin/streptomycin. Cells
were then resuspended in 1 ml neurobasalmedium con-
taining B27 (Invitrogen), 2 mM L-glutamin, 100 units/ml
penicillin/streptomycin, 20 ng/ml EGF, 20 ng/ml FGF-2,
and 2 μg/ml heparin. Cells were seeded into 6-well plates
at a concentration of 25,000–100,000 cells/ml, and incu-
bated at 37°C in 5 % CO2. Two thirds of the medium vol-
ume was changed weekly [23].
Immunocytochemistry
Neural stem cells were dissociated and plated on poly-L-
ornithin/laminin-coated 96-well plates at a density of 30
000 cells/well. After 2 days stem cells were washed with
PBS (Gibco) (37°C) and fixed with 4% paraformaldehyde
for 10 min on ice. Then, cells were washed with PBS (4°C)
and stored at 4°C. Cells were incubated for 10 min in 50
mM glycine in PBS, and then washed with PBS. After per-
meabilisation on ice using 0.2% TritonX-100 (Sigma) in
PBS, cells were incubated with blocking solution (1% BSA
in PBS) at room temperature. The GM-CSF receptor alpha
antiserum (1:100, Santa Cruz) and the nestin antiserum
(1:100, BD Transduction Laboratories) were incubated
over night at 4°C. Cells were then washed with 0.1% BSA
in PBS, and incubated for 1 h with the secondary antibod-
ies (anti-rabbit-FITC and anti-mouse TRITC, 1:200; dian-
ova) at room temperature. Cells were then washed briefly
in 0.1% BSA in PBS, and stained with Hoechst 33342
(Molecular Probes) (1:10000 in PBS).
PCR on GM-CSFRalpha
RNA of neurospheres of the hippocampus or SVZ was iso-
lated using the Qiagen RNeasy mini kit following the
manufacturers recommendations. cDNA was synthesized
from 5 μg total RNA using oligodT primers, superscript II
reverse transcriptase (Gibco) using standard conditions.
PCR was performed for the GM-CSFR alpha chain (BR4-
4s96: ACG TCG TTG GCT CAG TTA TGT C; BR4-4as272:
ATTTATGTCAGAGATGGAGGATGG, product length 176
bp) using 60°C annealing and 32 cycles. Products were
visualized by agarose gel electrophoresis, and ethidium
bromide staining.
Quantitative PCR
Neurospheres derived from the subventricular zone (SVZ)
were stimulated with 10 ng/ml recombinant human GM-
CSF (Leukine®, Immunex/Schering)(n = 3). 3 days after
addition of GM-CSF, cells were harvested for the RNA-
preparation, whereas untreated cells (n = 3) served as con-
trol. RNA of the GM-CSF-treated and untreated neuro-
spheres of the SVZ was isolated using the Qiagen RNeasy
mini kit following the manufacturers recommendations.
cDNA was synthesized from 5 μg total RNA using oligodT
primers, superscript II reverse transcriptase (Gibco) using
standard conditions. Quantitative PCR was performed
using the Lightcycler system (Roche Diagnostics, Man-
nheim, Germany) with SYBR-green staining of DNA dou-
blestrands. Cycling conditions were as follows: beta III-
tubulin: 3 min 95°C, 5 sec 95°C, 10 sec 65°C, 30 sec
72°C; 10 sec 87°C for 50 cycles; NSE (neuron specific
enolase): 3 min 95°C, 5 sec 95°C, 10 sec 58°C, 30 sec
72°C; 10 sec 81°C for 50 cycles; PLP: 3 min 95°C, 5 sec
95°C, 10 sec 62°C, 30 sec 72°C; 10 sec 84°C for 50
cycles; GFAP: 3 min 95°C, 5 sec 95°C, 10 sec 60°C, 30 sec
72°C; 10 sec 81°C for 50 cycles. Melting curves were
determined using the following parameters: 95°C cooling
to 50°C; ramping to 99°C at 0.2°C/sec. The following
primer pairs were used: "rat beta III-tub-716s" CCA CCT
ACG GGG ACC TCA ACC AC, "rat beta III-tub-1022as"
GAC ATG CGC CCA CGG AAG ACG, "rat NSE-plus" GGCBMC Neuroscience 2007, 8:88 http://www.biomedcentral.com/1471-2202/8/88
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AAG GAT GCC ACT AAT GT, "rat NSE -minus" AGG GTC
AGC AGG AGAC TTG A, "rat PLP-518s" TCA TTC TTT
GGA GCG GGT GTG, "rat PLP-927as" TAA GGA CGG
CAA AGT TGT AAG TGG, "rat GFAP3'-1123s" CCT TTC
TTA TGC ATG TAC GGA G, "rat GFAP3'-1245as" GTA
CAC TAA TAC GAA GGC ACT C. The Lightcycler PCR was
performed using the SYBR green master mix, following
the manufacturers recommendations (Roche diagnos-
tics). Specificity of product was ensured by melting point
analysis and agarose gel electrophoresis. cDNA content of
samples was normalized to the expression level of Cyclo-
philin (primers: "cyc5" ACC CCA CCG TGT TCT TCG AC,
"acyc300" CAT TTG CCA TGG ACA AGA TG). Relative reg-
ulation levels were derived after normalization to cyclo-
philin, and comparison to the untreated cells.
Luciferase assay
To generate the pGL3-p-βIII-tubulin experimental vector,
the class III β-tubulin gene promoter (fragment -450 -
+54) [24] was inserted into the pGL3-Basic firefly luci-
ferase reporter vector (Promega) as described before [6].
Cultivation of stem cells, DNA-transfection and luciferase
assay were carried out as described before [6]. Briefly, stem
cells were seeded at a density of 35 000 cells/well and were
cotransfected with the pGL3-p-βIII-tubulin vector and a
Renilla luciferase construct with the Lipofectamine
method (Invitrogen) 24 h after plating. Following the
incubation of transfected cells for 24 h, cells were stimu-
lated with various concentrations of GM-CSF in Neuroba-
sal medium (0.5 ng/ml, 5 ng/ml, 10 ng/ml) for 48 h. As
positive control for in vitro differentiation, stem cells were
treated by withdrawing mitogens and adding 5% fetal calf
serum (FCS). Using the Dual-Luciferase Reporter Assay
System (Promega) the ratio of luminescence signals from
firefly and renilla luciferase was obtained (Berthold Tech-
nologies, Mithras LB 940).
FACS analysis
For differentiation experiments, adult NSCs were plated in
15 cm2 culture flasks at a density of 4 million cells and
were treated once with 10 ng/ml GM-CSF (n = 3). A single
cell suspension was made by triturating the neurospheres
in 1 ml plastic pipettes, and then collected by centrifuga-
tion. After resuspension in 1× phosphate-buffered saline
(PBS), the cells were fixed with 1% PFA. The cells were
incubated for 15 min on ice, washed once with 1× PBS
and then permeabilised by resuspension in 0.2%
tween20. After an incubation on ice for 15 min, fetal calf
serum (FCS) was added in a 1:50 dilution for blocking.
The cells were incubated for 2 h on ice with a MAP2 anti-
body (Sigma; 1:50) and washed three times with 0.1%
tween20. Following an incubation for 30 min on ice with
a donkey anti-mouse FITC-conjugated secondary anti-
body (Dianova), the cells were washed again three times
with 0.1% tween20, and finally resuspended in 1× PBS for
FACS analysis. Flow cytometry of cells was performed on
a FACSCalibur (Becton-Dickinson).
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